



Welcome to the SPINRAZA community.

13,000+ people and 4,600+
adults have been treated
with SPINRAZA worldwide.*

*Based on commercial patients, early access patients,
and clinical trial participants through May 2022.



NICOLE // AGE 45

LATER-ONSET SMA
TREATED WITH SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

SELECTED IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Please see additional Important Safety Information and click for full [Prescribing Information](#).



REGISTER FOR A STEP EVENT

Take advantage of our free educational events as part of the Support and Treatment Education Program (STEP) series. These events offer an opportunity to learn more about SPINRAZA® (nusinersen). Register at [SPINRAZA.com/events](https://www.spinraza.com/events).



CONNECT WITH US ONLINE

EXPLORE OUR SPINRAZA CHANNELS



[Facebook](#)



[Instagram](#)



[Twitter](#)

Register to receive additional resources and support at [SPINRAZA.com/signup](https://www.spinraza.com/signup).

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please click for full [Prescribing Information](#).

This information is not intended to replace discussions with your healthcare provider.



©2023 Biogen. All rights reserved.
06/23 SPZ-US-3688 v2
225 Binney Street, Cambridge, MA 02142

